HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)

HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. They currently have a $15.00 price target on the biopharmaceutical company’s stock.

ABEO has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $5.78 on Wednesday. The company’s fifty day moving average is $5.65 and its two-hundred day moving average is $5.81. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a market cap of $251.26 million, a P/E ratio of -2.15 and a beta of 1.43.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. boosted its holdings in Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC boosted its holdings in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after purchasing an additional 386,321 shares in the last quarter. abrdn plc boosted its holdings in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Jane Street Group LLC boosted its holdings in Abeona Therapeutics by 894.8% in the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after purchasing an additional 118,262 shares in the last quarter. Finally, 683 Capital Management LLC boosted its holdings in Abeona Therapeutics by 17.3% in the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after purchasing an additional 116,845 shares in the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.